CorMedix Statistics
Total Valuation
CorMedix has a market cap or net worth of $605.63 million. The enterprise value is $496.39 million.
| Market Cap | 605.63M |
| Enterprise Value | 496.39M |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, before market open.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CorMedix has 77.94 million shares outstanding. The number of shares has increased by 40.04% in one year.
| Current Share Class | 77.94M |
| Shares Outstanding | 77.94M |
| Shares Change (YoY) | +40.04% |
| Shares Change (QoQ) | -0.54% |
| Owned by Insiders (%) | 7.42% |
| Owned by Institutions (%) | 49.18% |
| Float | 65.89M |
Valuation Ratios
The trailing PE ratio is 3.73.
| PE Ratio | 3.73 |
| Forward PE | n/a |
| PS Ratio | 1.31 |
| Forward PS | 2.43 |
| PB Ratio | 1.31 |
| P/TBV Ratio | 8.37 |
| P/FCF Ratio | 2.42 |
| P/OCF Ratio | 2.38 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.89, with an EV/FCF ratio of 1.98.
| EV / Earnings | 2.67 |
| EV / Sales | 1.07 |
| EV / EBITDA | 1.89 |
| EV / EBIT | 2.18 |
| EV / FCF | 1.98 |
Financial Position
The company has a current ratio of 2.56, with a Debt / Equity ratio of 0.32.
| Current Ratio | 2.56 |
| Quick Ratio | 2.23 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 0.56 |
| Debt / FCF | 0.59 |
| Interest Coverage | 81.68 |
Financial Efficiency
Return on equity (ROE) is 54.93% and return on invested capital (ROIC) is 55.18%.
| Return on Equity (ROE) | 54.93% |
| Return on Assets (ROA) | 24.56% |
| Return on Invested Capital (ROIC) | 55.18% |
| Return on Capital Employed (ROCE) | 31.71% |
| Weighted Average Cost of Capital (WACC) | 10.40% |
| Revenue Per Employee | $2.42M |
| Profits Per Employee | $973,901 |
| Employee Count | 191 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 1.88 |
Taxes
In the past 12 months, CorMedix has paid $16.23 million in taxes.
| Income Tax | 16.23M |
| Effective Tax Rate | 7.98% |
Stock Price Statistics
The stock price has decreased by -32.08% in the last 52 weeks. The beta is 1.50, so CorMedix's price volatility has been higher than the market average.
| Beta (5Y) | 1.50 |
| 52-Week Price Change | -32.08% |
| 50-Day Moving Average | 7.91 |
| 200-Day Moving Average | 8.12 |
| Relative Strength Index (RSI) | 44.27 |
| Average Volume (20 Days) | 875,390 |
Short Selling Information
The latest short interest is 16.03 million, so 20.57% of the outstanding shares have been sold short.
| Short Interest | 16.03M |
| Short Previous Month | 17.15M |
| Short % of Shares Out | 20.57% |
| Short % of Float | 24.33% |
| Short Ratio (days to cover) | 11.71 |
Income Statement
In the last 12 months, CorMedix had revenue of $462.25 million and earned $186.02 million in profits. Earnings per share was $2.08.
| Revenue | 462.25M |
| Gross Profit | 417.01M |
| Operating Income | 227.24M |
| Pretax Income | 203.40M |
| Net Income | 186.02M |
| EBITDA | 262.55M |
| EBIT | 227.24M |
| Earnings Per Share (EPS) | $2.08 |
Balance Sheet
The company has $256.69 million in cash and $147.46 million in debt, with a net cash position of $109.24 million or $1.40 per share.
| Cash & Cash Equivalents | 256.69M |
| Total Debt | 147.46M |
| Net Cash | 109.24M |
| Net Cash Per Share | $1.40 |
| Equity (Book Value) | 460.83M |
| Book Value Per Share | 5.93 |
| Working Capital | 293.16M |
Cash Flow
In the last 12 months, operating cash flow was $253.94 million and capital expenditures -$3.52 million, giving a free cash flow of $250.42 million.
| Operating Cash Flow | 253.94M |
| Capital Expenditures | -3.52M |
| Depreciation & Amortization | 35.31M |
| Net Borrowing | 149.50M |
| Free Cash Flow | 250.42M |
| FCF Per Share | $3.21 |
Margins
Gross margin is 90.21%, with operating and profit margins of 49.16% and 40.49%.
| Gross Margin | 90.21% |
| Operating Margin | 49.16% |
| Pretax Margin | 44.00% |
| Profit Margin | 40.49% |
| EBITDA Margin | 56.80% |
| EBIT Margin | 49.16% |
| FCF Margin | 54.17% |
Dividends & Yields
CorMedix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -40.04% |
| Shareholder Yield | -40.04% |
| Earnings Yield | 30.71% |
| FCF Yield | 41.35% |
Analyst Forecast
The average price target for CorMedix is $15.33, which is 97.30% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.33 |
| Price Target Difference | 97.30% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 3.47% |
| EPS Growth Forecast (3Y) | -8.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 26, 2019. It was a reverse split with a ratio of 1:5.
| Last Split Date | Mar 26, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
CorMedix has an Altman Z-Score of 2.57 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.57 |
| Piotroski F-Score | 5 |